We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

GE Healthcare

GE Healthcare provides medical imaging and information technologies, medical diagnostics, patient monitoring systems,... read more Featured Products: More products

Download Mobile App




GE HealthCare Spin-Off Targeted for January 2023

By MedImaging International staff writers
Posted on 14 Sep 2022
Image: GE HealthCare is on track toward future as a standalone public company leading precision health innovation (Photo courtesy of GE)
Image: GE HealthCare is on track toward future as a standalone public company leading precision health innovation (Photo courtesy of GE)

GE (Boston, MA, USA) has announced the first Board of Directors for GE HealthCare, the planned independent company that will be created following its spin-off from GE. The company also announced that it is targeting a spin-off date in the first week of January 2023, subject to final approval from the GE Board of Directors and other customary conditions.

As previously announced by GE, GE HealthCare will be the name of its healthcare business following its planned separation into three industry-leading, global, investment-grade public companies. GE intends to execute the tax-free spin-off of GE HealthCare in the first week of January 2023, creating an independent company driving innovation in precision health to improve patient outcomes and address critical patient and clinical challenges.

Building on a more than 100-year history, the GE HealthCare name and Monogram will serve as an enduring badge of safety, quality, trust, and innovation. The new brand color for GE HealthCare is called “compassion purple” to reflect more humanity and warmth and achieve greater distinction. The company will continue to be at the forefront of provider and patient care with more than four million product installations and over two billion patient exams a year.

Related Links:
GE 

Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Mammo DR Retrofit Solution
DR Retrofit Mammography
Ultrasound Needle Guidance System
SonoSite L25
Digital Radiography System
DR-300

Channels

General/Advanced Imaging

view channel
Image: The study developed a marker based on the analysis of routine CT scans of gastric cancer patients treated at UNICAMP. Higher radiodensity values for adipose tissue are linked to a worse prognosis. In contrast, higher values for muscle are linked to a more favorable outcome (Photo courtesy of FCM-UNICAMP)

CT-Derived Biomarker Predicts Outcomes in Gastric Cancer

Gastric cancer, also known as stomach cancer, is the fifth most common malignancy worldwide and often shows heterogeneous outcomes even within the same stage. Prognostic estimates typically rely on tumor-centric... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.